vs
Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
FIRSTSUN CAPITAL BANCORP is the larger business by last-quarter revenue ($110.0M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 6.9%).
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FSUN vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $110.0M | $86.8M |
| Net Profit | $21.6M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 19.6% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | -8.4% | — |
| EPS (diluted) | $0.76 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $86.8M | ||
| Q3 25 | $107.3M | $67.5M | ||
| Q2 25 | $105.6M | $60.0M | ||
| Q1 25 | $96.2M | $49.3M | ||
| Q4 24 | $98.7M | $73.7M | ||
| Q3 24 | $98.2M | $58.6M | ||
| Q2 24 | $96.2M | $31.1M |
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | — | ||
| Q3 25 | $23.2M | $-91.3M | ||
| Q2 25 | $26.4M | $-111.7M | ||
| Q1 25 | $23.6M | $-116.2M | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $22.4M | $-83.5M | ||
| Q2 24 | $24.6M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | -84.7% | ||
| Q3 25 | 26.4% | -140.7% | ||
| Q2 25 | 31.2% | -189.8% | ||
| Q1 25 | 30.9% | -245.8% | ||
| Q4 24 | 20.4% | -117.5% | ||
| Q3 24 | 29.1% | -152.1% | ||
| Q2 24 | 32.3% | -327.6% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 21.6% | -135.3% | ||
| Q2 25 | 25.0% | -186.2% | ||
| Q1 25 | 24.5% | -235.5% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 22.8% | -142.7% | ||
| Q2 24 | 25.5% | -312.2% |
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | — | ||
| Q3 25 | $0.82 | — | ||
| Q2 25 | $0.93 | $-0.33 | ||
| Q1 25 | $0.83 | $-0.36 | ||
| Q4 24 | $0.57 | $-0.24 | ||
| Q3 24 | $0.79 | $-0.28 | ||
| Q2 24 | $0.88 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $413.7M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $698.6M |
| Total Assets | $8.6B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $297.0M | ||
| Q3 25 | $659.9M | $300.8M | ||
| Q2 25 | $785.1M | $301.2M | ||
| Q1 25 | $621.4M | $359.7M | ||
| Q4 24 | $615.9M | $323.8M | ||
| Q3 24 | $573.7M | $397.5M | ||
| Q2 24 | $535.8M | $412.5M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $698.6M | ||
| Q3 25 | $1.1B | $702.3M | ||
| Q2 25 | $1.1B | $698.5M | ||
| Q1 25 | $1.1B | $767.9M | ||
| Q4 24 | $1.0B | $710.4M | ||
| Q3 24 | $1.0B | $773.5M | ||
| Q2 24 | $996.6M | $768.5M |
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $913.2M | ||
| Q3 25 | $8.5B | $904.9M | ||
| Q2 25 | $8.4B | $907.4M | ||
| Q1 25 | $8.2B | $966.7M | ||
| Q4 24 | $8.1B | $910.4M | ||
| Q3 24 | $8.1B | $991.1M | ||
| Q2 24 | $8.0B | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $-52.6M | ||
| Q3 25 | $49.4M | $-78.7M | ||
| Q2 25 | $15.0M | $-67.4M | ||
| Q1 25 | $26.4M | $-103.7M | ||
| Q4 24 | $101.1M | $-73.3M | ||
| Q3 24 | $48.1M | $-59.0M | ||
| Q2 24 | $20.9M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $-61.9M | ||
| Q3 25 | $47.6M | $-89.5M | ||
| Q2 25 | $13.0M | $-74.9M | ||
| Q1 25 | $24.3M | $-109.9M | ||
| Q4 24 | $95.7M | $-77.5M | ||
| Q3 24 | $47.1M | $-61.3M | ||
| Q2 24 | $19.9M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | -71.3% | ||
| Q3 25 | 44.4% | -132.7% | ||
| Q2 25 | 12.3% | -124.9% | ||
| Q1 25 | 25.3% | -222.8% | ||
| Q4 24 | 97.0% | -105.1% | ||
| Q3 24 | 47.9% | -104.6% | ||
| Q2 24 | 20.6% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 10.7% | ||
| Q3 25 | 1.6% | 16.1% | ||
| Q2 25 | 1.9% | 12.4% | ||
| Q1 25 | 2.1% | 12.6% | ||
| Q4 24 | 5.5% | 5.7% | ||
| Q3 24 | 1.1% | 3.9% | ||
| Q2 24 | 1.1% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | — | ||
| Q3 25 | 2.13× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
